Skip to main content

Abivax S.A.

AAVXF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001956827

No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.

Other share classesABVX

Key figures

Market capADS ratio not in SEC data
–
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026
0
13F valueReported value at the end of Q3 2026
$0
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in EUR.

Revenue, FY2025
EUR 4.57M
−63.3% year over year
Net income, FY2025
EUR -336.1M
No comparable prior period
Free cash flow, FY2025
EUR -161.3M
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: EUR 336.1M (7354.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
166.6K
Shares sold short
Change
−556.6K
−77.0% vs. previous
Days to cover
> 999
Above FINRA's cap of 999.99 days

Superinvestors holding AAVXF, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding AAVXF at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Abivax S.A. insiders from Form 4, newest first.

No open-market purchases or sales by Abivax S.A. insiders are on file.

Top 10 13F holders, Q3 2026

View all: Top 10 13F holders, Q3 2026

The largest institutional positions in Abivax S.A. at the end of Q3 2026; share changes are against Q2 2026.

No institution reported holding AAVXF in 13F filings for Q3 2026.